查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529802

新生兒毒理學市場規模、佔有率、趨勢分析報告：按檢體、按藥物、按技術、按最終用途、按地區、細分市場預測，2024-2030 年

Neonatal Toxicology Market Size, Share & Trends Analysis Report By Specimen (Urine, Umbilical Cord), By Drug (Cannabinoids, Opioids), By Technology, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

新生兒毒理學市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球新生兒毒性市場規模將達到5.1405億美元，預計2024年至2030年複合年成長率為10.6%。

由於孕產婦吸毒導致的新生兒禁忌症（NAS）等新生兒疾病的盛行率不斷增加，推動了對新生兒毒理學檢測和治療的需求。此外，質譜儀等先進診斷技術的發展正在改善新生兒有毒物質暴露的檢測和管理，從而推動市場成長。

這一令人震驚的趨勢凸顯了對有效的新生兒毒性解決方案的迫切需求。在過去的幾十年裡，藥物篩檢工具取得了顯著進步，現在可以提供比以往更準確和精確的結果。傳統上，藥物測試是使用酵素結合免疫吸附檢測法（ELISA）進行的。這種方法有幾個優點。它相對便宜，易於在一般實驗室中執行，並且週轉時間短。此外，由於 ELISA 多年的使用，一些市售抗體已被檢驗可用於多種人體組織。對於某些測試，例如檢測尿液中的可卡因代謝物，ELISA 是一種可靠的方法。然而，其他藥物和組織組合的假陽性和陰性發生率相對較高。

此外，馬薩諸塞州最大的醫療保健系統麻省總醫院布里格姆分校宣布將在 2024 年 4 月對嬰兒出生時暴露於毒品的可疑虐待或忽視行為的報告方式進行重大改變。耶魯紐黑文兒童醫院和波士頓醫療中心等系統也採用了這一政策轉變，這是針對懷孕期間吸毒採取更加富有同情心、基於證據的應對措施的更廣泛努力的一部分，它顯示了一種趨勢。這些機構不會報告所有出生時接觸藥物的案例，而是只會報告他們有合理理由相信嬰兒面臨身體或心理傷害風險的病例。這種方法反映了一種日益成長的共識，即懲罰性措施會導致父母和兒童的健康狀況惡化，並對有色人種家庭和社會經濟地位較低的家庭產生不成比例的影響。這種不斷變化的政策格局對新生兒毒理學檢測產業具有重大影響。從懲罰性方法轉向更具支持性和康復性的措施預計將推動新生兒毒理學檢測的需求和利用的變化。

康乃狄克州、新墨西哥州、華盛頓州和科羅拉多等州法律的變化，以及麻州一項懸而未決的法案，旨在保護服用處方藥治療藥物濫用障礙的母親，測試標準可能會變得更加複雜。這可能會導致更有針對性的測試，更有效地利用資源，並且僅在絕對必要時進行測試。此外，隨著市場轉向支持性護理，提供全面、微創篩檢解決方案的新技術具有巨大的成長潛力。這包括高解析度質譜和創新生物標記等技術的進步，使我們能夠更詳細地了解新生兒的暴露和健康狀況，而無需進行重大侵入性手術。

新生兒毒理學市場報告亮點

  • 根據檢體，胎糞在 2023 年的收益佔有率最大。糞便檢體透過檢測懷孕後期的藥物暴露，提供更長的檢測窗口，在新生兒毒性方面具有重要優勢。
  • 質譜法是新生兒毒性的黃金標準，為檢測納克級藥物暴露提供無與倫比的靈敏度和特異性。其優點包括準確度高、檢測極限低以及能夠從初步篩檢中確認陽性結果。
  • 從藥物來看，大麻素細分市場佔據主導地位，2023 年市場佔有率最大。懷孕期間大麻素的使用呈上升趨勢，有 2-5% 的孕婦自我報告使用大麻素，其中低收入都市區女性的比例高達 28%。這種增加是由於合法化、安全意識以及用於噁心。
  • 按最終用途分類，臨床測試領域在 2023 年佔據最大的銷售佔有率。 Arup Laboratories 和 Quest Diagnostics 是市場上的主要參與者，提供全面的檢測服務來檢測產前藥物暴露。
  • 由於存在大量主要市場參與者、新生兒藥物暴露率高以及對產前藥物濫用的不良影響的認知不斷增強，北美在市場上佔據主導地位。
  • 預計 2024 年至 2030 年預測期內，亞太地區將呈現最快的複合年成長率。擴大醫療基礎設施和實施旨在減少懷孕期間藥物濫用的公共衛生舉措預計將推動該地區的市場成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章新生兒毒理學市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 新生兒毒理學市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 新生兒毒性市場：檢體估計與趨勢分析

  • 2023年及2030年按檢體分類的市場佔有率佔有率
  • 細分儀表板
  • 檢體的全球新生兒毒性市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第5章新生兒毒理學市場：技術估算與趨勢分析

  • 2023 年和 2030 年按技術市場佔有率
  • 細分儀表板
  • 按技術展望分類的全球新生兒毒理學市場
  • 2018-2030年市場規模、預測及趨勢分析

第6章新生兒毒性市場：依藥物類型估計與趨勢分析

  • 2023 年和 2030 年按藥物類型分類的市場佔有率佔有率
  • 細分儀表板
  • 按藥物類型分類的全球新生兒毒性市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第7章新生兒毒理學市場：最終用戶的估計和趨勢分析

  • 2023 年和 2030 年最終用戶的市場佔有率
  • 細分儀表板
  • 按最終用戶分類的全球新生兒毒性市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第8章新生兒毒理學市場：區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Quest Diagnostics Incorporated
    • USDTL
    • Quidel Corporation
    • Thermo Fisher Scientific, Inc.
    • Omega Laboratories, Inc.
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Laboratory Corporation of America Holdings
    • Clinical Reference Laboratory, Inc.
    • Cordant Health Solutions
Product Code: GVR-4-68040-358-5

Neonatal Toxicology Market Growth & Trends:

The global neonatal toxicology market size is expected to reach USD 514.05 million by 2030, at a projected CAGR of 10.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of neonatal disorders, such as neonatal abstinence syndrome (NAS) due to maternal drug use, drives the demand for neonatal toxicology testing and treatments. In addition, the development of advanced diagnostic technologies, such as mass spectrometers, improves the detection and management of toxic exposures in neonates, thereby propelling market growth.

This alarming trend underscores the urgent need for effective neonatal toxicology solutions. Over the past several decades, there have been significant advancements in drug screening tools, which now provide more accurate and precise results than ever before. Traditionally, drug testing has been performed using enzyme-linked immunosorbent assays (ELISAs). This method has several advantages: it is relatively inexpensive, easy to perform in a general laboratory, and has a rapid turnaround time. Moreover, the long-standing use of ELISA has resulted in the availability of multiple commercial antibodies validated for use in various human tissues. For certain tests, such as detecting cocaine metabolites in urine, ELISA is a reliable method. However, for other drug and tissue combinations, there is a relatively high incidence of both false positives and negatives.

In addition, Mass General Brigham, Massachusetts' largest healthcare system, in April 2024 announced a significant shift in its approach to reporting suspected abuse or neglect in cases where a baby is born exposed to drugs. This policy change, now adopted by systems like Yale New Haven Children's Hospital and Boston Medical Center, signifies a broader trend toward more compassionate and evidence-based responses to substance use during pregnancy. Rather than reporting every instance of drug exposure at birth, these health systems will only report if there is reasonable cause to believe the infant is at risk of physical or emotional injury. This approach reflects a growing consensus that punitive measures lead to worse medical outcomes for both parent and child and disproportionately impact families of color and those with low socioeconomic status. This evolving policy landscape has profound implications for the neonatal toxicology testing industry. The shift away from punitive approaches towards more supportive and rehabilitative measures is expected to drive changes in the demand and utilization of neonatal toxicology tests.

With revised state laws in places like Connecticut, New Mexico, Washington, and Colorado and pending legislation in Massachusetts to protect mothers on prescribed medications for substance use disorder, the criteria for conducting toxicology tests may become more refined. This could lead to more targeted testing, ensuring that resources are used efficiently and that testing is conducted only when truly necessary. In addition, as the market shifts towards supportive care, there is significant potential for growth in emerging technologies that offer comprehensive and minimally invasive screening solutions. This includes advancements in technologies like high-resolution mass spectrometry and innovative biomarkers that can provide more detailed insights into neonatal exposure and health without extensive invasive procedures.

Neonatal Toxicology Market Report Highlights:

  • Based on the specimen, meconium accounted for the largest revenue share in 2023. Meconium specimens offer a key advantage in neonatal toxicology by detecting drug exposure over the last trimester of pregnancy, providing a longer detection window.
  • Based on technology, mass spectroscopy dominated the market in 2023.Mass spectrometry is the gold standard in neonatal toxicology, offering unparalleled sensitivity and specificity for detecting drug exposure at nanogram levels. Its advantages include high accuracy, low detection limits, and the ability to confirm positive results from initial screenings.
  • Based on the drug, the cannabinoids segment dominated the market in 2023 with the largest market share. Cannabinoid use during pregnancy is rising, with 2-5% of pregnant women self-reporting use and rates as high as 28% among low-income urban women. This increase is driven by legalization, perceived safety, and use for nausea.
  • Based on end use, the clinical laboratories segment dominated the market with the largest revenue share in 2023. Arup Laboratories and Quest Diagnostics are key players in the market, providing comprehensive testing services to detect prenatal drug exposure.
  • North America dominated the market due to the presence of a large number of major market players, the high prevalence of neonatal drug exposure, and the increasing awareness of the adverse effects of prenatal drug abuse.
  • The Asia Pacific region is expected to witness the fastest CAGR over the forecast period from 2024 to 2030. Due to the expansion of healthcare infrastructure and the implementation of public health initiatives aimed at reducing drug abuse during pregnancy, market growth is expected in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Specimen
    • 1.2.2. Technology
    • 1.2.3. Drug
    • 1.2.4. End User
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Specimen outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Drug outlook
    • 2.2.4. End User outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Neonatal Toxicology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of substance abuse
      • 3.2.1.2. Stringent laws mandating alcohol and drug testing
      • 3.2.1.3. Increasing government initiatives to monitor substance abuse
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Neonatal toxicology is considered a violation of privacy rights in some countries
  • 3.3. Neonatal Toxicology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Neonatal Toxicology Market: Specimen Estimates & Trend Analysis

  • 4.1. Specimen Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Neonatal Toxicology Market by Specimen Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Urine
      • 4.4.1.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Umbilical Cord
      • 4.4.2.1. Umbilical cord market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Meconium
      • 4.4.3.1. Meconium market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Neonatal Toxicology Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Neonatal Toxicology Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Mass spectroscopy
      • 5.4.1.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Immunoassay
      • 5.4.2.1. Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Neonatal Toxicology Market: Drug type Estimates & Trend Analysis

  • 6.1. Drug type Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Neonatal Toxicology Market by Drug type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cannabinoids
      • 6.4.1.1. Cannabinoids Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Opioids
      • 6.4.2.1. Opioids Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Cocaine
      • 6.4.3.1. Cocaine Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Benzodiazepines
      • 6.4.4.1. Benzodiazepines market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Amphetamines
      • 6.4.5.1. Amphetamines Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Other illicit drugs
      • 6.4.6.1. Other illicit drugs Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Neonatal Toxicology Market: End User Estimates & Trend Analysis

  • 7.1. End User Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Neonatal Toxicology Market by End User Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospitals
      • 7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Clinical Laboratories
      • 7.4.2.1. Clinical Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Neonatal Toxicology Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/ Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/ Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Quest Diagnostics Incorporated
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Others benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. USDTL
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Others benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Quidel Corporation
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Others benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Thermo Fisher Scientific, Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Others benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Omega Laboratories, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Others benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Bio-Rad Laboratories, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Others benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Agilent Technologies, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Others benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Laboratory Corporation of America Holdings
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Others benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Clinical Reference Laboratory, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Others benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Cordant Health Solutions
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Others benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 4 North America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 6 North America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 8 U.S. neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 10 U.S. neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 12 Canada neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Canada neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Canada neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 16 Mexico neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Mexico neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 18 Mexico neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 21 Europe neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 23 Europe neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 25 Germany neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Germany neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 29 UK neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 31 UK neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 33 France neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 34 France neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 35 France neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 37 Italy neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Italy neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Italy neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 41 Spain neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Spain neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 43 Spain neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 45 Denmark neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 46 Denmark neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 47 Denmark neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 49 Sweden neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Sweden neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Sweden neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 53 Norway neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 54 Norway neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 55 Norway neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 62 China neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 63 China neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 64 China neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 66 Japan neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 67 Japan neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 68 Japan neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 70 India neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 71 India neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 72 India neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 74 South Korea neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 75 South Korea neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 76 South Korea neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 78 Australia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 79 Australia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 80 Australia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 82 Thailand neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 83 Thailand neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 84 Thailand neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 86 Latin America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 87 Latin America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 88 Latin America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Brazil neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 90 Brazil neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Brazil neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 92 Brazil neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 93 Argentina neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 94 Argentina neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 95 Argentina neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 96 Argentina neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 97 MEA neonatal toxicology market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 99 MEA neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 100 MEA neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 101 MEA neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 102 South Africa neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 103 South Africa neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 105 South Africa neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 110 UAE neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 111 UAE neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 113 UAE neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
  • Table 114 Kuwait neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
  • Table 115 Kuwait neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
  • Table 117 Kuwait neonatal toxicology market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Neonatal toxicology market: market outlook
  • Fig. 14 Neonatal toxicology competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Neonatal toxicology market driver impact
  • Fig. 20 Neonatal toxicology market restraint impact
  • Fig. 21 Neonatal toxicology market strategic initiatives analysis
  • Fig. 22 Neonatal toxicology market: Specimen movement analysis
  • Fig. 23 Neonatal toxicology market: Specimen outlook and key takeaways
  • Fig. 24 Urine market estimates and forecast, 2018 - 2030
  • Fig. 25 Umbilical cord estimates and forecast, 2018 - 2030
  • Fig. 26 Meconium market estimates and forecast, 2018 - 2030
  • Fig. 27 Others market estimates and forecast, 2018 - 2030
  • Fig. 28 Neonatal toxicology Market: Technology movement analysis
  • Fig. 29 Neonatal toxicology market: Technology outlook and key takeaways
  • Fig. 30 Mass spectroscopy market estimates and forecasts, 2018 - 2030
  • Fig. 31 Immunoassay market estimates and forecasts,2018 - 2030
  • Fig. 32 Neonatal toxicology market: Drug movement analysis
  • Fig. 33 Neonatal toxicology market: Drug outlook and key takeaways
  • Fig. 34 Cannabinoids market estimates and forecast, 2018 - 2030
  • Fig. 35 Opioids estimates and forecast, 2018 - 2030
  • Fig. 36 Amphetamines market estimates and forecast, 2018 - 2030
  • Fig. 37 Cocaine market estimates and forecast, 2018 - 2030
  • Fig. 38 Benzodiazepines market estimates and forecast, 2018 - 2030
  • Fig. 39 Others illicit drugs market estimates and forecast, 2018 - 2030
  • Fig. 40 Neonatal toxicology market: End use movement analysis
  • Fig. 41 Neonatal toxicology market: End use outlook and key takeaways
  • Fig. 42 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 43 Clinical Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030
  • Fig. 45 Global neonatal toxicology market: Regional movement analysis
  • Fig. 46 Global neonatal toxicology market: Regional outlook and key takeaways
  • Fig. 47 Global neonatal toxicology market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America
  • Fig. 55 North America market estimates and forecasts, 2018 - 2030
  • Fig. 56 U.S. key country dynamics
  • Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 58 Canada key country dynamics
  • Fig. 59 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 60 Mexico key country dynamics
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 62 Europe
  • Fig. 63 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 64 UK key country dynamics
  • Fig. 65 UK market estimates and forecasts, 2018 - 2030
  • Fig. 66 Germany key country dynamics
  • Fig. 67 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 68 France key country dynamics
  • Fig. 69 France market estimates and forecasts, 2018 - 2030
  • Fig. 70 Italy key country dynamics
  • Fig. 71 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 72 Spain key country dynamics
  • Fig. 73 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 74 Denmark key country dynamics
  • Fig. 75 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 76 Sweden key country dynamics
  • Fig. 77 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 78 Norway key country dynamics
  • Fig. 79 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 82 China key country dynamics
  • Fig. 83 China market estimates and forecasts, 2018 - 2030
  • Fig. 84 Japan key country dynamics
  • Fig. 85 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 86 India key country dynamics
  • Fig. 87 India market estimates and forecasts, 2018 - 2030
  • Fig. 88 Thailand key country dynamics
  • Fig. 89 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 90 South Korea key country dynamics
  • Fig. 91 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 92 Australia key country dynamics
  • Fig. 93 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 94 Latin America
  • Fig. 95 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 96 Brazil key country dynamics
  • Fig. 97 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 98 Argentina key country dynamics
  • Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 100 Middle East and Africa
  • Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 102 South Africa key country dynamics
  • Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 Saudi Arabia key country dynamics
  • Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 106 UAE key country dynamics
  • Fig. 107 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 108 Kuwait key country dynamics
  • Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 110 Market share of key market players - Neonatal toxicology market